For Immediate Release
March 23. 2020

Contact: ***JDavis@corgenix.com***

CORGENIX READY TO ASSIST DIAGNOSTIC FIRMS WITH EUA ON COVID-19

Broomfield, CO- March 23, 2020. Corgenix Medical Corporation, a global contract research organization and ISO 13485:2016 IVD manufacturer with a 30-year track record in drug development and biomarker discovery, is uniquely qualified and ready to assist diagnostic firms in their quest for EUA on COVID-19.

This positioning is based not only on our MDSAP certification, our robust GCP procedures or our compliance with the applicable sections of GLP 21 CFR Part 58, but also on our addition of the Corgenix Clinical Laboratory. This CAP-accredited, CLIA-certified analytical, clinical and usability testing suite enhances our ability to offer one-stop shopping to our assay development partners.

CCL is platform and methodology agnostic, and we can customize our testing and development space as well as our staff around your idea to provide speed, accuracy and clinical utility to your project. Our flexibility and our ability to pivot coupled with our experience in the ELISA and molecular space ensures our adherence to whatever your protocol dictates.

Our leadership and staff possess a rich history of successful submissions to regulatory bodies both here in the U.S. and with global regulatory bodies. Our end-to-end, client-centric approach provides our partners with the confidence that their product will be brought to market while meeting the clinical, procedural and financial needs of today's tumultuous marketplace.

Corgenix has three decades of experience with development, manufacturing and distribution of immunodiagnostic solutions. Our experience and expertise cover the assay development continuum and our services focus on four key areas – Development, Clinical, Quality & Regulatory, and Manufacturing – enabling us to deliver products and services that remove burdens, reduce risk and instill confidence with our partners.

Our CLIA-certified, CAP-accredited laboratory allows us to provided additional services to our partners, ranging from research, reproducibility and clinical study testing, to LDT and single-site IVD development. Our test menu continues to grow as we add new tests, across multiple disease areas, on a regular basis.

As an FDA-registered ISO13485:2016-certified facility, we are in compliance with global medical device and In Vitro Diagnostic (IVD) regulations and standards ensuring that the services we offer are of the highest quality. We support our partners' assay development, testing and manufacturing needs as well U.S. and global registrations and commercialization requirements.

To connect with Corgenix regarding COVID-19, please email: jdavis@corgenix.com.

To learn more about Corgenix, please visit: www.corgenix.com.